Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 2, 2006, Pages 398-405

  Lin, Zu Yau ^a   Chuang, Wan Long ^a   Chuang, Yen Hwang ^a   Yu, Ming Lung ^a   Hsieh, Ming Yuh ^a   Wang, Liang Yen ^a   Tsai, Jung Fa ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Amphotericin B; Chemosensitivity test; Epirubicin; Liver neoplasms; Primary culture

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETIC ACID DERIVATIVE; AMPHOTERICIN B; EPIRUBICIN; TRYPSIN ETHYLENEDIAMINE TETRAACETIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BILE DUCT CARCINOMA; CANCER CELL; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE TECHNIQUE; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SYSTEMIC THERAPY; ULTRASOUND;

EID: 33645223477     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04026.x     Document Type: Article

References (35)

1. Falkson G Coetzer B Chemotherapy of primary liver cancer. In: Okuda K Ishak KG, eds Neoplasms of the Liver Tokyo Springer 1987 321 6
2. Mizumoto R Kawarada Y Diagnosis and treatment of cholangiocarcinoma and cystic adenocarcinoma of the liver. In: Okuda K Ishak KG, eds Neoplasms of the Liver Tokyo Springer 1987 381 96
3. Plosker GL Faulds D Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy Drugs 1993 45 788 856
4. Ravdin PM Anthracycline resistance in breast cancer: clinical applications of current knowledge EurJCancer 1995 31A Suppl. 7 S11 14
5. Coukell AJ Faulds D Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer Drugs 1997 53 453 82
6. Kaye SB Reversal of multidrug resistance Cancer TreatRev 1990; 17 suppl. A 37 43
7. Hargrave RM Davey MW Davey RA Kidman AD Development of drug resistance is reduced with idarubicin relative to other anthracyclines Anticancer Drugs 1995 6 432 7
8. Mross K Bohn C Edler L et al. Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society AnnOncol 1993 4 11 13
9. Wishart GC Bissett D Paul J et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial JClinOncol 1994 12 1771 7
10. Dogliotti L Berruti A Buniva T et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial JClinOncol 1996 14 1165 72
11. Ozols RF Hogan WM Grotzinger KR McCoy W Young RC Effects of amphotericin B on adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and L1210 leukemia Cancer Res 1983 43 959 64
12. Krishan A Sauerteig A Gordon K Effect of amphotericin B on adriamycin transport in P388 cells Cancer Res 1985 45 4097 102
13. Vertut-Croquin A Brajtburg J Medoff G Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1-(2-chloroethyl)-3- cyclohexyl-1-nitrosourea against the human promyelocytic leukemia cell line HL-60 Cancer Res 1986 46 6054 8
14. Stewart DJ Evans WK Non-chemotherapeutic agents that potentiate chemotherapy efficacy Cancer TreatRev 1989 16 1 40
15. Bergstrom P Grankvist K Holm S Henriksson R Effects of antimicrobial drugs on the cytotoxicity of epirubicin, bleomycin, estramustine and cisplatin Anticancer Res 1991 11 1039 44
16. Morikage T Bungo M Inomata M et al. Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line Jpn JCancer Res 1991 82 747 51
17. Morikage T Ohmori T Nishio K Fujiwara Y Takeda Y Saijo N Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines Cancer Res 1993 53 3302 7
18. Kikkawa F Kojima M Oguchi H et al. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells Anticancer Res 1993 13 891 6
19. Assem M Bonvalot S Beltramo JL et al. Deleterious effect of serum protein on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells BrJCancer 1994 70 631 5
20. Kojima M Kikkawa F Oguchi H et al. Potentiation of cis-diammine (1,1-cyclobutanedicarboxylato) platinum (II) by amphotericin B in BALB/c nude mice bearing human ovarian carcinoma cells Jpn JCancer Res 1994 85 1159 64
21. Beketic-Oreskovic L Osmak M Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells Cancer ChemotherPharmacol 1995 35 327 33
22. Poulain L Sichel F Crouet H et al. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells Cancer ChemotherPharmacol 1997 40 385 90
23. Ferguson PJ Currie C Vincent MD Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II Drug MetabDispos 1999 27 1399 405
24. Vukovic L Osmak M Reversal of carboplatin resistance in human laryngeal carcinoma cells Neoplasma 1999 46 335 41
25. Krutchik AN Buzdar AU Blumenschein GR Sinkovics JG Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma Cancer TreatRep 1978 62 1565 7
26. Presant CA Bartolucci AA Lowenbraun S Effects of amphotericin B on combination chemotherapy of metastatic sarcoma Cancer 1984 53 214 18
27. Presant CA Metter GE Multhauf P et al. Effects of amphotericin B with combination chemotherapy on response rates and on survival in non-small cell carcinoma of the lung Cancer TreatRep 1984 68 651 4
28. Presant CA Multhauf P Metter G Reversal of cancer chemotherapeutic resistance by amphotericin B: a broad phase I-II pilot study EurJClinOncol 1987 23 683 7
29. González-Manzano R Vieitez JM Tangco E De Alava EF Herranz P Garcia-Foncillas J Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas AmJClinOncol 1993 16 332 7
30. Hu OY Chang SP Jame JM Chen KY Pharmacokinetic and pharmacodynamic studies with 4′-epidoxorubicin in nasopharyngeal carcinoma patients Cancer ChemotherPharmacol 1989 24 332 7
31. Medoff G Brajtburg J Kobayashi GS Antifungal agents useful in therapy of systemic fungal infections AnnRevPharmacolToxicol 1983 23 303 30
32. Sabra R Branch RA Amphotericin B nephrotoxicity Drug Saf 1990 5 94 108
33. Morasca L Erba E Flow cytometry. In: Freshney RI, ed. Animal Cell Culture Oxford IRL Press 1986 125 48
34. Reiners JJ Jr. Mathieu P Okafor C Putt DA Lash LH Depletion of cellular glutathione by conditions used for the passaging of adherent cultured cells ToxicolLett 2000 115 153 63
35. Takayasu K Okuda K Celiac angiography in the diagnosis of small hepatocellular carcinoma. In: Okuda K Ishak KG, eds Neoplasms of the Liver Tokyo Springer 1987 279 87